INTRINSIC: A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Sponsor: Hoffmann-La Roche
Full Title
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Study Treatment
KRAS G12C inhibitor Divarasib + FOLFOX or FOLFIRI
Eligibility/Info
- First or second line KRAS G12C mutant colorectal cancer
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.